– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes –
Read more at prnewswire.comImmunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PR Newswire -
Mon Oct 9, 2023
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Electric%20car%20being%20recharged%20by%20Choochart%20Choochaikupt%20via%20iStock.jpg)
/Qualcomm%2C%20Inc_%20logo%20on%20phone-by%20viewimage%20via%20Shutterstock.jpg)